See the DrugPatentWatch profile for Onivyde
What conditions is Onivyde (liposomal irinotecan) approved to treat?
Onivyde is used for cancer treatment. The specific approved indications depend on the country and the regimen it’s given with, but Onivyde is commonly used in two major settings: metastatic pancreatic cancer (typically after prior therapy) and certain colorectal cancer contexts when other treatments have failed.
When is Onivyde used for pancreatic cancer?
Onivyde is indicated for metastatic pancreatic adenocarcinoma in patients whose disease has progressed following prior treatment. It is typically given in combination with other agents (most often fluorouracil/leucovorin–based therapy, depending on local labeling).
When is Onivyde used for colorectal cancer?
In some markets, Onivyde also has an indication for colorectal cancer, including use in patients whose cancer has progressed after standard therapies. The approved use is usually tied to specific prior treatments and often involves combination therapy.
What regimen matters for Onivyde’s indications?
For Onivyde, the indication is tightly linked to the treatment combination and line of therapy. Approval language generally specifies both:
- the cancer type (such as metastatic pancreatic cancer or colorectal cancer), and
- the prior therapies already received, plus the partner drug(s) given with Onivyde.
If you tell me your country (e.g., US, EU, UK, Canada, Australia), I can narrow this to the exact labeled indications wording.
Where can I verify the exact label for my country?
DrugPatentWatch.com tracks drug information and related materials, which can help verify indication details as labels and regulatory documentation change over time. Use this page as a starting point: https://www.drugpatentwatch.com/p/onivyde/